Evolocumab and clinical outcomes in patients with cardiovascular disease
File(s)
Accepted version
Author(s)
Hadjiphilippou, S
Ray, KK
Type
Journal Article
Abstract
ischaemic heart disease remains the leading cause of death
worldwide.
1
decades of research have established that the
accumulation of the cholesterol cargo carried by low density
lipoprotein particles within the arterial wall is the initiating
factor in atherogenesis and its clinical manifestation as
coronary artery disease. large scale epidemiological studies,
mendelian randomisation genetic studies and trials of
therapeutic interventions have established that low density
lipoprotein cholesterol (ldl-C) is a causal factor in developing
atherosclerotic heart disease.
2–5
the mainstay of therapy for
reducing ldl-C has so far been with statin therapy initially
followed by add-on therapy. despite current lipid lowering
therapies, a proportion of patients either fail to reach their
target ldl-C with statins or are intolerant to statins thus
limiting treatment options. While ezetimibe can be used as an
add-on or alternative to statins, the modest 20% reduction in
ldl-C precludes more widespread use. there is therefore, an
unmet need for further ldl-C reduction with new treatments,
among those with high atherosclerotic cardiovascular disease
risk such as those with prevalent disease or with familial
hypercholesterolaemia.
worldwide.
1
decades of research have established that the
accumulation of the cholesterol cargo carried by low density
lipoprotein particles within the arterial wall is the initiating
factor in atherogenesis and its clinical manifestation as
coronary artery disease. large scale epidemiological studies,
mendelian randomisation genetic studies and trials of
therapeutic interventions have established that low density
lipoprotein cholesterol (ldl-C) is a causal factor in developing
atherosclerotic heart disease.
2–5
the mainstay of therapy for
reducing ldl-C has so far been with statin therapy initially
followed by add-on therapy. despite current lipid lowering
therapies, a proportion of patients either fail to reach their
target ldl-C with statins or are intolerant to statins thus
limiting treatment options. While ezetimibe can be used as an
add-on or alternative to statins, the modest 20% reduction in
ldl-C precludes more widespread use. there is therefore, an
unmet need for further ldl-C reduction with new treatments,
among those with high atherosclerotic cardiovascular disease
risk such as those with prevalent disease or with familial
hypercholesterolaemia.
Date Issued
2017-06-01
Date Acceptance
2017-05-25
Citation
Journal of the Royal College of Physicians of Edinburgh, 2017, 47 (2), pp.153-155
ISSN
1478-2715
Publisher
Royal College of Physicians of Edinburgh
Start Page
153
End Page
155
Journal / Book Title
Journal of the Royal College of Physicians of Edinburgh
Volume
47
Issue
2
Copyright Statement
This article is available under a Creative Commons Attribution-NonComercial CC BY-NC licence https://creativecommons.org/licenses/by-nc/4.0
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/28675189
Subjects
General & Internal Medicine
Publication Status
Published
Coverage Spatial
Scotland